Brookline analyst Kemp Dolliver initiated coverage of Radiopharm (RADX) with a Buy rating and $18 price target The clinical stage company’s pipeline of radiopharmaceutical candidates features novel combinations of targeting moieties, isotopes, and tumor types and is early stage with six of seven programs at either the preclinical stage or in Phase 1, notes the analyst. The company’s most advanced candidate, RAD101, is an imaging candidate for brain metastases that is in a Phase 2b study with data from the first two cohorts expected in Q3, the analyst points out.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RADX:
- Radiopharm, Cyclotek signs clinical supply agreement for Tb-KLK3-mAb
- Radiopharm Theranostics Limited – American Depositary Shares trading resumes
- Radiopharm granted U.S. FDA FTD for RAD101
- Radiopharm announces dosing of first patient in Phase 1 HEAT trial
- Radiopharm reports preclinical Lu177-B7H3-mAb data